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Knowledge of the genetic basis of the type 2 diabetes (T2D)-related quantitative traits fasting glucose (FG) and insulin (FI) in African
ancestry (AA) individuals has been limited. In non-diabetic subjects of AA (n ¼ 20,209) and European ancestry (EA; n ¼ 57,292), we per-
formed trans-ethnic (AAþEA) fine-mapping of 54 established EA FG or FI loci with detailed functional annotation, assessed their rele-
vance in AA individuals, and sought previously undescribed loci through trans-ethnic (AAþEA) meta-analysis. We narrowed credible
sets of variants driving association signals for 22/54 EA-associated loci; 18/22 credible sets overlappedwith active islet-specific enhancers
or transcription factor (TF) binding sites, and 21/22 contained at least one TFmotif. Of the 54 EA-associated loci, 23 were shared between
EA and AA. Replication with an additional 10,096 AA individuals identified two previously undescribed FI loci, chrX FAM133A
(rs213676) and chr5 PELO (rs6450057). Trans-ethnic analyses with regulatory annotation illuminate the genetic architecture of glycemic
traits and suggest gene regulation as a target to advance precision medicine for T2D. Our approach to utilize state-of-the-art functional
annotation and implement trans-ethnic association analysis for discovery and fine-mapping offers a framework for further follow-up
and characterization of GWAS signals of complex trait loci.Introduction
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individuals for genetic study and, taking advantage of
differences in linkage disequilibrium (LD) patterns across
EA and AA, used a trans-ethnic analytic approach to
improve mapping resolution15 and narrow the number
of potential causal SNPs at associated loci.15,16 We then
characterized predicted SNP function with detailed anno-
tation information from diverse sources. We hypothe-
sized that a trans-ethnic approach would identify SNPs
with high likelihood of having regulatory, causal func-
tion, with results illuminating mechanisms underlying
glycemic regulation in African Americans as well as
whites of European ancestry.
We created the African American Glucose and Insulin
Genetic Epidemiology (AAGILE) Consortium, with up
to 20,209 AA individuals from 16 cohorts, to conduct a
fixed effects meta-analysis of association summary statis-
tics at 3.3 million (HapMap2) SNPs for levels of FG and
body mass index (BMI)-adjusted FI. We then combined
meta-analysis results from AAGILE with those from the
EA Meta-Analyses of Glucose and Insulin-related traits
Consortium (MAGIC, n ¼ 57,292)10 with three aims in
mind: (1) conduct trans-ethnic fine-mapping of 54
T2D QT loci (36 FG, 16 FI, 2 associated with both FG
and FI) identified from EA and combine fine-mapping
with annotation resources including RegulomeDB,
ENCyclOpedia of DNA Elements (ENCODE), Islet Regu-
lome, and Functional ANnotation of The mammalian
genOMe Consortium (FANTOM);11–14 (2) assess the bio-
logic relevance (allelic heterogeneity, transferability, pop-
ulation genetic selection, and consistency of association
with T2D or insulin resistance traits) of the 54 EA FG
and FI loci in AA individuals; and (3) identify additional
FG and FI variants by combining association results from
AAGILE and MAGIC using Meta-Analysis of TRans-
ethnic Association Studies (MANTRA)15 followed by de
novo or in silico replication in additional AA samples
(n up to 10,096) for 62 potential additional SNPs that
met pre-specified significance levels from the trans-
ethnic meta-analysis. The study design is illustrated in
Figure S1 and characteristics of each participating cohort
are described in Table S1.Material and Methods
Research Participants
A total of 20,209 (for FG) and 17,871 (for FI) non-diabetic men and
women of African ancestry (AA) from 16 cohorts participated in
stage 1 (Table S1). Additionally, up to 10,096 (for FG) and 6,669
(for FI) non-diabetic individuals from 14 cohorts were included
in a stage 2 replication analyses. Participants were excluded from
this study if they had a diagnosis of T2D by a physician, were on
any diabetes treatment, or had a FG concentration equal to or
greater than 7 mmol/L. HbA1c levels were not used as diagnostic
criteria. FG and FI GWAS data for 57,292 (FG) and 52,328 (FI) EA
individuals were obtained from MAGIC.10 Each participating
study has obtained institutional review board approval and all
subjects provided written informed consent.58 The American Journal of Human Genetics 99, 56–75, July 7, 2016Genetic Variants
Genotyping was conducted in each cohort using commercially
available genome-wide SNP arrays with quality control criteria
for variants before imputation listed in Table S1. In all stage 1
discovery analyses, imputation was performed to infer ungeno-
typed variants and fill in missing genotypes. We used phased
haplotype data from the CEU and YRI HapMap phase 2 samples
for the majority of contributing studies, using MACH17 or
IMPUTE2.18 Variants with lower imputation quality scores
(MACH r2 < 0.30 or IMPUTE2 information score < 0.40) were
excluded from further analyses. Approximately 3.3 million
directly genotyped or imputed SNPs, including ~78,000 from the
X chromosome, passed the quality control filters and were evalu-
ated for association.
Traits and Covariates
In all cohorts, fasting blood samples were obtained from par-
ticipants after an overnight (R8 hr) fast. Detailed descriptions
of study-specific FG and FI measurements are given in
Table S1. Analyses of untransformed levels of FG and natural
logarithm-transformed FI were adjusted for age, age squared,
sex, and principal components (PC) for ancestry. In addition,
we adjusted FI levels for BMI to reduce confounding by
obesity.10 SNP-trait associations were tested using additive ge-
netic models. Additional cohort-specific covariates (like study
center for cohorts with multiple sites or relatedness for studies
containing families) were included at the discretion of each
cohort (Table S1).
Overview of Study Design and Analysis Strategy
The overall study design is shown in Figure S1. We first performed
fixed-effect meta-analyses of FG and FI in AA samples. We then
conducted trans-ethnic meta-analyses by combining the fixed-ef-
fect meta-analysis results from AAGILE with MAGIC. We fine-
mapped FG and FI loci previously identified in EA by constructing
99% credible sets.15 Second, we used results from the fixed-
effect meta-analysis in AA to assess whether FG and FI loci
identified in EA populations have genetic concordance or biolog-
ical relevance in AA. Third, we carried forward 62 SNPs (not previ-
ously described to be associated with FG or FI in persons of EA)
based on low fixed-effect meta-analysis p values in AA or high
log-Bayes factor (log(BF)) in the combined AA and EA trans-ethnic
analysis for follow-up in additional non-diabetic samples of AA to
identify additional FG and FI association signals. Specifically, the
threshold for SNP promotion to replication was a fixed-effect
meta-analysis p < 10–6 in AA samples, or p < 10–5 with log(BF)
> 5 in MANTRA. Meta-analyses were performed at two different
sites and summary statistics were crosschecked to ensure consis-
tency of results.
Meta-analysis of Samples from AAGILE and MAGIC
Consortia
Each participating study from the AAGILE consortium performed
a cohort-specific association analysis under an additive genetic
model to test the genetic association of each genetic variant
with FG and FI. The cohort-specific genome-wide association re-
sults were corrected with genomic control, unless lGC < 1, before
meta-analyzing the GWAS results.17We then conducted a fixed-ef-
fects meta-analysis with inverse-variance weighting implemented
in the programMETAL to aggregate the cohort-specific association
results.19
To leverage differential patterns of LD between common vari-
ants in EA and AA populations, we meta-analyzed GWAS results
from AA in AAGILE and previously published EA results from
MAGIC10 using the Meta-ANalysis of Trans-ethnic Association
Studies (MANTRA) software.15,20 The results from MANTRA were
used to fine-map the 54 loci (36 FG, 16 FI, 2 associated with
both FG and FI) previously identified in EA samples and to priori-
tize variants for discovery of previously undescribed variants asso-
ciated with FG and FI in AA samples.Construction of 99% Credible Sets
To improve fine-mapping resolution, we first constructed 99%
credible sets for previously reported FG and FI loci identified in
EA samples (36 FG, 16 FI, 2 associated with both FG and FI).8–10
We identified the genomic region 250 kb upstream and 250 kb
downstream of the lead SNP from the EA meta-analysis and
defined BFk, obtained from MANTRA analysis, as the Bayes factor
for SNP k. We calculated the posterior probability that SNP k is
functional or tagging an unobserved causal SNP by BFk=
P
iBFi,
where i indexes SNPs in the locus of interest. The 99% credible
sets are the collection of the minimum number of variants
providing a cumulative posterior probability greater or equal to
0.99 for representing the causal variant at a given locus.21Annotation of Credible Set SNPs
We focused our annotation analysis on loci that showed a 99%
credible set reduction of at least 20% in the length of the genomic
interval spanned by the variants in the credible set or in the num-
ber of variants included in the credible set (13 FG, 8 FI loci, and 1
locus for both FG and FI). When examining the distribution of
credible set reduction across all 54 FG and FI loci, we noted that
there appeared to be a natural break point between 20% and
12%, so we selected 20% reduction as a threshold defining loci
with substantial reduction. At these loci, we classified SNPs in
the credible set into two groups: one group with SNPs included
in the 99% credible set from the trans-ethnic fine-mapping with
MANTRA and a second group that included only SNPs that were
included in the 99% credible set using EA samples (MAGIC) but
were excluded from the trans-ethnic 99% credible set. For brevity,
we henceforth refer to these categories of SNPs as the ‘‘narrowed
sets’’ and ‘‘excluded sets,’’ respectively.
To compare functional annotation of the narrowed versus
excluded credible sets, we annotated SNPs from the narrowed
and excluded sets separately using the HaploReg tool that searches
for dbSNP annotation (synonymous substitution, non-synony-
mous substitution, lying within an intron, 50 UTR, 30 UTR, or
lncRNA, conservation in mammals, or having unknown position
or function), genomic position, distance to the nearest named
known protein-coding gene, eQTL data, and transcription factor
motif, transcription factor binding site (TFBS), DNASe hypersensi-
tivity (DHS), and histonemarks associated with promoters and en-
hancers derived from the ENCODE and Roadmap Epigenomics
consortia.12 We dichotomized the data from HaploReg for each
SNP in the narrowed and excluded sets based on whether there
was evidence of each specific annotation. To compare the narrow
and excluded sets of SNPs for each trait, we performed a Fisher’s
exact test to assess differences in proportions of SNPs in each set
with a specific annotation characteristic.
We visually examined overlap between trait association and reg-
ulatory annotation by plotting association statistics and regulato-
ry data together. For each of the 22 loci with a reduction in the sizeThof at least 20% (either length of or the count of SNPs included in)
of the 99% credible set after trans-ethnic analysis, we used Regulo-
meDB to generate a single numeric score summarizing the
strength of regulatory data associated with each SNP in the locus
(within 250 kb on either side of the index SNP for that locus
from MAGIC).11 In brief, RegulomeDB uses data from ENCODE
and other published literature to annotate SNPs based on overlap
with TFBS, TF motifs, DHS, eQTLs, and promoter histone marks
and creates a score for each SNP ranging from 1 to 7, with 1 corre-
sponding to the strongest degree of regulatory annotation, 6 cor-
responding to the weakest degree of regulatory annotation, and
7 representing no data available. We then used statistical software
R to make regional association plots as described above using the
log(BF) for each SNP as the association statistic, with the color of
each plotted SNP corresponding to its RegulomeDB score and
the size of each plotted SNP corresponding to LD with the MAGIC
index SNP in the YRI population. Finally, to visually examine over-
lap between the 99% credible regions at these 22 loci and regula-
tory data derived from pancreatic islets, we used the Islet Regu-
lome Browser to generate plots with the same coordinates as
represented in the regional plots and aligned the schematic repre-
sentation of islet-derived regulatory annotation from the Islet Reg-
ulome Browser to the regional association plot.13
We performed additional annotation analyses for the narrowed
set (from the trans-ethnic meta-analysis). The starting and ending
chromosome position of the 99% credible region from the trans-
ethnic analysis for each of the 22 loci with substantially reduced
99% credible sets were entered into the Islet Regulome Browser,
and we cataloged the presence/absence of binding sites for five
transcription factors (FOXA2, MAFB, NKX2.2, NKX6.1, PDX1) or
the insulator protein CTCF, and histone marks associated with
promoters, active enhancers, and inactive enhancers.11,13 In
addition to examining overlap between credible set SNPs and reg-
ulatory annotation, we also manually annotated the credible set
intervals for the 22 loci with substantially reduced 99% credible
sets. The genomic interval for each narrowed trans-ethnic credible
set was examined in the UCSCGenome Browser, and we cataloged
RNA expression, DHS sites, TFBS, and promoter and enhancer his-
tone marks in cell types relevant to FG and FI, namely liver,
pancreatic, adipose, and muscle.Genomic Annotation Enrichment Analysis
We tested for enrichment of chromatin statemarks and TFBS using
all variants in the trans-ethnic meta-analysis credible sets. We
pooled chromatin states for promoter (TssA, TssFlnk) and
enhancer (EnhA, EnhWk) elements for 93 cell types (after
excluding cancer lines) from the Roadmap Epigenomics Con-
sortium22 and used TF binding data for 165 proteins from
ENCODE23 and the Islet Regulome.13 For a given annotation, we
calculated the cumulative posterior probability of annotated vari-
ants at each locus and then averaged these values across all loci.
We then generated a null distribution for this procedure by
randomly shuffling the probabilities among variants at each locus,
recalculating the average probability for annotated variants, and
repeating this procedure 1,000,000 times. We estimated fold-
enrichment for each annotation by dividing the observed value
by the permuted value averaged across all permutations. We
then calculated a p value for the enrichment as the proportion
of permutations for which the resulting value was greater than
or equal to that observed. We applied a corrected significance
threshold of 0.00019 (0.05/257 annotations).e American Journal of Human Genetics 99, 56–75, July 7, 2016 59
Interrogation of Transferability across Populations
We investigated the transferability to AA of EA FG- and FI-associ-
ated SNPs and loci. To evaluate SNP transferability, we tested in
AA the association of index FG and FI SNPs from EA individuals
in MAGIC8–10 (i.e., EA FG or FI SNPs with p < 5 3 10–8). We
defined SNP transferability as an EA index SNP showing in AA
an association that was statistically significant (p < 0.05) and
consistent in direction of effect as in the EAmeta-analysis. To eval-
uate locus transferability, given differences in local LD structure
across populations, we also interrogated the flanking5250 kb re-
gions of the index SNP in AA to search for any SNPs with a smaller
association p than the EA index SNP. For locus transferability, we
used a Bonferroni corrected p to determine the significance for
each locus by adjusting for the effective number of independent
tests within that locus, using the Li and Ji approach.24
Conditional Analysis of Signals with Significant SNP
Associations in AA
We performed approximate conditional association analyses at
loci with significant QT associations in AAGILE in order to test
whether the associated AAGILE SNP was the same association
signal as the MAGIC SNP. We used genome-wide complex trait
analysis (GCTA)25 for this analysis, because it allows approximate
conditional analyses in results from meta-analysis without the
need for individual cohort data to conduct the tests. GCTA
approximated the variance-covariance matrix of genotype using
estimated allele frequency from the meta-analysis results and LD
between SNPs from a reference sample. We calculated the associa-
tion of the AA best SNP conditional on the EA index SNP within
the same locus in AA samples.
Concordance Analysis across Ancestry Groups
For this analysis, we considered SNPs that passed QC and had a
MAF > 1% in both EA- and AA-specific meta-analyses. We further
excluded (1) EA-associated FG or FI loci, defined as those lying 500
kb upstream or downstream of previously reported SNPs for each
loci as described,16 and (2) AT/GC SNPs to avoid the potential
bias introduced by the strand misalignment between EA- and
AA-specific meta-analysis. We then classified all the remaining
SNPs into categories based on the association p value in the
MAGIC EA samples: p % 0.01, 0.01 < p % 0.5, and 0.5 < p % 1.
For the SNPs within each category, we then selected a set of inde-
pendent SNPs by identifying the most significant SNP, omitting
the SNPs within 500 kb region apart from the most significant
SNP, and then repeating this process until there were no more
SNPs left. We then determined the direction of effect for the EA
trait-raising allele between EA and AA samples and we calculated
the proportion of these selected SNPs that share the same direction
of effect. To determine the significance of the excess in concor-
dance (with 50% expected), we then conducted one-sided bino-
mial tests.
Population Differentiation and Natural Selection at
QT Loci
We applied several approaches to evaluate population differentia-
tion and natural selection at index FG or FI SNPs, using the trait-
raising allele in EA as the risk allele. First, we compared the risk-
allele frequencies in EA versus AA by calculating the absolute value
difference between the risk-allele frequency in EA and the risk-
allele frequency in AA for each index SNP. Second, we used
Wright’s fixation index26 (Fst) to measure the degree of the popu-60 The American Journal of Human Genetics 99, 56–75, July 7, 2016lation differentiation due to genetic drift and reflected by the
divergent allele frequencies. A value of Fst lying in range of 0 to
0.05 indicates little genetic differentiation; a value 0.05 to 0.15,
moderate differentiation; and a value greater than 0.15, greater
population differentiation.27,28 We calculated Fst using risk-allele
frequencies obtained from AAGILE cohorts for AAs and from
MAGIC8–10 for EAs. We also calculated the Fst using CEU and
YRI HapMap2 data from two samples of equal size to ensure that
the imbalance in sample size of our EA and AA samples does not
obscure the population differentiation at any locus. Third, we
used Haplotter29 to calculate the integrated haplotype score
(iHS) in HapMap2 data to measure the amount of extended haplo-
type homozygosity and hence the evidence of recent positive se-
lection at the index SNP. Fourth, we compared the effect alleles
from the index SNP of each locus against the human genome to
determine whether it was the major or minor allele using the
UCSC Genome Browser GRCh37/hg19 version, produced by the
Genome Reference Consortium in 2009.30Associations of QT Loci with T2D and Insulin
Resistance-Related Traits in AA Individuals
As described below, we assembled new African ancestry cohort
data sources for triglycerides and initiated collaborations with
new and existing consortia for body mass index (BMI), waist-to-
hip ratio adjusted for BMI (WHRadjBMI), systolic and diastolic
blood pressure, hypertension (HTN), and low-density and high-
density lipoprotein cholesterol (LDL-C and HDL-C) to investigate
the association of T2D QT SNPs with T2D and insulin resistance-
related traits (BMI, WHRadjBMI, HTN, LDL-C, HDL-C, and triglyc-
erides) in AA individuals. Specifically, we investigated the associa-
tion of 25 SNPs, including 24 most associated SNPs (14 FG, 9 FI,
and 1 SNP, rs780094, associated with both FG and FI) residing in
the regions demonstrating locus transferability in AA and 1 previ-
ously undescribed FI SNP (rs6450057). We also tested the associa-
tion of the FI SNP on chromosome X, rs213676, with lipid traits
(the only traits available for chromosome X). HapMap2-imputed
GWASmeta-analysis summary statistics for 25 SNPs were obtained
from theMeta-analysis of T2D in African Americans (MEDIA) con-
sortium for T2D31 (n up to 23,818), the African Ancestry Anthro-
pometry Genetics Consortium (AAAGC) for BMI32 (n up to
39,141) andWHRadjBMI32,33 (n up to 19,049), and the Continen-
tal Origins and Genetic Epidemiology Network (COGENT) for
HTN and blood pressure34 (n up to 29,828). HapMap-imputed
GWASmeta-analysis summary statistics for 26 SNPs were obtained
from the Candidate gene Association Resource (CARe) consortium
for LDL-C and HDL-C35 (n up to 8,090) and the ElectronicMedical
Records and Genomics Network (eMERGE) for triglycerides36 (n
up to 2,838). SNPs with p < 0.05 and same direction of effect
(i.e., FG/FI-increasing alleles associated with T2D or higher levels
of the quantitative insulin-resistance traits, except for HDL-C
where FG/FI-increasing alleles were expected to be associated
with lower HDL-C) were considered significant.Discovery and Replication of Previously Undescribed
FG and FI SNPs in AA
For identification of additional FG- and FI-associated loci in AA, we
took a two-stage (discovery followed by replication) approach
(Figure S1). In the discovery stage, we used fixed-effect meta-anal-
ysis results in AA and the trans-ethnic meta-analysis (MANTRA) re-
sults as described in the Meta-analysis of Samples from AAGILE
and MAGIC Consortia section. We identified 62 variants, not
previously reported to be associated with FG or FI in any ancestry,
classified into three tiers of decreasing restrictiveness based on low
fixed-effect meta-analysis p values in AA or high trans-ethnic
meta-analysis (MANTRA) log(BF) in the combined AA and EA re-
sults, for follow-up in 10,096 additional AA samples from 16 addi-
tional, independent cohorts (Table S1). Identified variants were
classified into three tiers to take forward to the replication stage.
Tier 1 was variants with a fixed-effect meta-analysis p < 10–6 in
AA samples, or p < 10–5 with log(BF) > 5 in MANTRA; tier 2 was
variants with log(BF) > 4 and fixed-effect p < 10–5; and tier 3
was variants with log(BF) > 4 or fixed-effect p < 10–5 (Figure S1).
The 16 additional independent replication cohorts are listed in
Table S1. For replication, we sought either in silico look-ups of the
62 SNPs that met criteria for one of the three tiers from the discov-
ery stage in the cohorts with extant genotyping array data or con-
ducted de novo genotyping for SNPs in tier 1 in additional cohorts
with DNA and trait levels. Each participating replication cohort
implemented the same model used for discovery analyses to
evaluate associations between SNPs and traits. First we compared
discovery and replication results for significance and direction of
effect. Then we meta-analyzed the discovery and replication stage
results to obtain a combined, fixed effect inverse variance estimate
for each of the 62 SNPs. Genome-wide statistical significance was
set at p% 5 3 10–8, and associations were considered to be previ-
ously undescribed if they were not in LD (r2 < 0.3 or not within
500 kb of a previously reported glycemia-associated SNP).
Finally, we performed a trans-ethnic meta-analysis in MANTRA
combining fixed effects estimates from the AAGILE discovery and
replication combined meta-analysis with published EA results
from MAGIC to get a trans-ethnic total effect size using all avail-
able data for 62 SNPs. We considered an association to have
reached genome-wide significance if the p% 5 3 10–8 in fixed-ef-
fect meta-analysis or log(BF) from MANTRA was greater than 6,
and we considered the association to be previously undescribed
if the variants were not in LD (r2 < 0.3) or not within 500 kb of
a SNP previously reported to be associated with FG or FI.Results
Trans-ethnic Fine-Mapping and Annotation of
Glycemic QT Loci Established in EA Populations
To fine-map 54 loci previously associated with FG or FI in
EA,8–10 we constructed 99% credible sets, the smallest set
of SNPs that accounts for 99% of the posterior probability
of containing the causal variant at the locus, using meta-
analysis results only from MAGIC EA samples and trans-
ethnic meta-analysis results from both MAGIC EA samples
and AAGILE AA samples (Table S2). Reflecting increased
sample size and differences in LD structure between
ancestry groups, trans-ethnic meta-analyses yielded more
than 20% reduction in either the number of SNPs or the
genomic interval spanned by the SNPs in credible sets for
22/54 loci (13 FG, 8 FI, and 1 associated with both FG
and FI; Table 1 and Figures S2 and S3) while we also
observed some loci with substantially enlarged credible
sets. For 4 of these 22 loci (GCK [MIM: 138079] and
ADCY5 [MIM: 600293] for FG, PPP1R3B [MIM: 610541]
for FI, and GCKR [MIM: 600842] for both) with a >20%
reduction in the credible set, the credible set included a sin-Thgle SNP. We observed the greatest reduction (95%) in the
number of SNPs in the credible set at the FOXA2 locus,
where the genomic width of the credible set was also
greatly reduced (from ~46 kb to ~4 kb; 92% reduction),
and the extent of LD surrounding the index SNP was less
in AA than EA (Figure 1). The narrowed trans-ethnic CSs
contained previously described functional variants at
several loci, including the coding SNP rs1801282 (Gen-
Bank: NC_000003.12; g.12351626C>G [p.Pro12Ala]) in
PPARG (MIM: 601487)37 and rs7903146 in TCF7L2
(MIM: 602228), which has been shown to overlap an islet
enhancer and modify enhancer activity.38 In contrast, the
coding SNP rs1260326 at the GCKR locus, presumed to be
causal based on prior studies,39,40 was excluded from the
99% credible set. With the exception of non-synonymous
variants at DPYSL5 (MIM: 608383), COBLL1 (MIM:
610318)-GRB14 (MIM: 601524), and PPARG (Table 2), the
greatly reduced credible sets mapped predominantly to
non-coding sequences.
At 22 loci with a >20% reduction in the credible set, we
compared functional annotations of SNPs in the trans-
ethnically generated credible sets (‘‘narrowed’’ set) to those
of SNPs excluded from the EA-only credible sets
(‘‘excluded’’ set) using HaploReg annotation.12 For the nar-
rowed set of nine FI loci, the SNP annotation from dbSNP
indicated only a reduction in intronic SNPs and an in-
crease in unknown function SNPs compared to the
excluded set (Table S3). However, regulatory annotation
data showed that the narrowed set of nine FI loci was en-
riched for enhancer-associated chromatin marks and
eQTLs when compared to the excluded set (76.3% versus
66.0%, p ¼ 0.004 for enhancer marks; 39.4% versus
28.5%, p ¼ 0.002 for eQTLs [Table S3]). At the 14 FG loci,
we observed an enrichment of SNPs in 30 UTR of genes,
but no enrichment of regulatory annotations in the nar-
row set compared to the excluded set (Table S4). Table S5
provides annotation information from HaploReg for each
SNP in these 22 derived credible sets, and the Supple-
mental Note and Table S6 show results from more exten-
sive annotation from publicly available regulatory data.
As an example, manual annotation of the FOXA2 locus
shows that the top SNP lies just upstream of an lncRNA,
LINC00261, with evidence for expression in liver and
pancreas and overlapping numerous TFBSs in liver cell
lines (Supplemental Note). This and prior evidence that
this lncRNA can regulate FOXA2 expression41 implicate
the lncRNA as a possible causal transcript at this locus.
To more specifically examine whether variants at the 22
loci with greatly narrowed credible sets were enriched for
individual TFBS or cell-type-specific chromatin marks, we
employed a permutation test. We observed significant
enrichment (p < 1.9 3 10–4) for FG loci at binding sites
for MAFB (p ¼ 2 3 10–6), NKX2-2 (p ¼ 2 3 10–6), FOXA2
(p ¼ 1.6 3 10–5), and PDX1 (p ¼ 1.0 3 10–4) as well as
for chromatin marks in pancreatic islets (p ¼ 1.2 3 10–4)
(Figure 2A, Table S7). Among FI loci, we observed nomi-
nally significant enrichment for chromatin marks ine American Journal of Human Genetics 99, 56–75, July 7, 2016 61
Table 1. 22 EA-Associated Type 2 Diabetes Quantitative Traits Loci with Substantially Reduced 99% Credible Sets Based on Trans-ethnic
Fine Mapping
Locusa Chr
99% Credible Set: European Ancestry Only 99% Credible Set: Trans-ethnic 99% Credible Set Reduction
# SNPsb Rangec (bp) # SNPsb Rangec (bp) % SNPsd % Rangee
Fasting Glucose-Associated Loci
FOXA2 20 40 46,365 2 3,872 95.0 91.6
GCK 7 7 25,107 1 1 85.7 100.0
KL 13 696 496,262 147 492,550 78.9 0.7
ADCY5 3 4 31,042 1 1 75.0 100.0
GCKR 2 2 11,663 1 1 50.0 100.0
PROX1 1 11 18,286 6 13,550 45.5 25.9
DPYSL5 2 87 294,065 50 269,667 42.5 –8.3
IGF2BP2 3 64 317,522 38 355,236 40.6 –11.9
CDKN2B-ANRIL 9 7 5,914 5 4,515 28.6 23.7
ADRA2A 10 33 68,716 26 68,110 21.2 0.9
TCF7L2 10 5 36,312 4 15,268 20.0 58.0
FADS1 11 20 58,394 16 57,823 20.0 1.0
DGKB-TMEM195 7 11 143,605 10 2,182 9.1 98.5
CRY2 11 10 57,088 11 14,850 –10.0 74.0
Fasting Insulin-Associated Loci
ARL15 5 319 498,585 22 33,535 93.1 93.3
PPP1R3B 8 8 9,510 1 1 87.5 100.0
COBLL1-GRB14 2 14 51,528 3 11,540 78.6 77.6
IRS1 2 43 137,640 13 68,951 69.8 49.9
GCKR 2 3 11,663 1 1 66.7 100.0
FAM13A 4 43 243,374 21 243,374 51.2 0.0
ANKRD55-MAP3K1 5 417 497,027 218 487,103 47.7 2.0
UHRF1BP1 6 13 217,136 9 136,609 30.8 37.1
PPARG 3 14 60,448 11 56,618 21.4 6.3
The 22 EA-associated T2D QT loci include 13 fasting glucose, 8 fasting insulin, and 1 associated with both. Substantial reduction is defined as greater than 20%
reduction in its genomic length or the number of SNPs.
aFor ease of comparison to previous studies, the loci are named based on the historically identified nearest protein-coding gene or genes to the index SNP in Eu-
ropean ancestry.
b# SNPs is the number of SNPs included in the 99% credible set.
cRange is defined as the maximum genomic distance based on hg18 among the SNPs included in the 99% credible set.
d%SNPs is (the number of SNPs in the EA-based 99% credible set the number of SNPs in the trans-ethnic analysis-based 99% credible set)/the number of SNPs in
the EA-based 99% credible set.
e%Range is (the range of the EA-based 99% credible set  the range of the trans-ethnic analysis-based 99% credible set)/the range of the EA-based 99%
credible set.adipose cells (p ¼ 0.048) and for several TFBSs such as
MAFK (p ¼ 0.0038) and RXRA (p ¼ 0.0071) (Figure 2A,
Table S7).
We incorporated information from RegulomeDB and the
Islet Regulome Browser11,13 to better visualize the relation-
ship between trait association and regulatory annotation
at the 22 loci with >20% reduction in the 99% credible
sets. Of the 14 FG loci, seven (CRY2 [MIM: 603732],
DPYSL5, FADS1 [MIM: 606148], FOXA2, GCKR, IGF2BP2
[MIM: 608289], and KL [MIM: 604824]) contained a SNP
with a RegulomeDB score % 3, consistent with moderate62 The American Journal of Human Genetics 99, 56–75, July 7, 2016evidence for regulatory function (Figure S4). At four of
these seven loci (CRY2, FADS1, FOXA2, and GCKR), the
same SNP with strong regulatory annotation also had
genome-wide significant evidence of association in the
trans-ethnic meta-analysis (log(BF) > 6) (Figures 2B, 2C,
and S4). Similarly, of the nine FI loci with reduced credible
set size, six of the credible regions (ANKRD55 [MIM:
615189]-MAP3K1 [MIM: 600982], ARL15, FAM13A [MIM:
613299], GCKR, PPARG, and UHRF1BP) contained a SNP
with a RegulomeDB score % 3, and at three of these loci
(GCKR, PPARG, and UHRF1BP1), the SNP with strong
Figure 1. Trans-ethnic Analysis of
Glycemic Quantitative Loci Provides Nar-
rowed Intervals Spanned by the 99%
Credible Set
Data are 500 kb regional association plots
for fasting glucose at FOXA2, centered at
the index SNP identified from European
ancestry (EA) samples. The x axis denotes
genomic position and the y axis denotes
the log (BF), recombination rate, and
varLD information61 (a measure to quan-
tify LD variation differences comparing
populations). The red diamond data point
represents the index SNP within the region
previously reported from EA samples. The
color of each data point indicates its LD
value (r2) with the index SNP based on
HapMap2 (YRI for AA results and CEU
for EA results): white, r2 not available;
blue, r2 ¼ 0.0–0.2; brown, r2 ¼ 0.2–0.5; or-
ange, r2 ¼ 0.5–0.8; red, r2 ¼ 0.8–1.0. The
blue line represents the recombination
rate. The green line shows the varLD score
at each SNP and is highlighted with dark
brown if the varLD score is >95th per-
centile of the genome-wide varLD score,
comparing LD information between YRI
and CEUHapMap2 samples.61 The interval
spanned by the 99% credible set is high-
lighted in pink.
(A) Association results for fasting glucose in
the FOXA2 region in EA individuals. The
99% credible set contains 40 SNPs that
span an interval of 46,365 bp.
(B) Association results for fasting glucose in
the FOXA2 region in AA individuals. The
association signal is weaker than in EA
samples, leading to a wider interval
spanned by the 99% credible set.
(C) Association results for fasting glucose
in the FOXA2 region in both EA and AA in-
dividuals. The 99% credible set contains 2
SNPs and spans an interval of 3,872 bp, a
95% reduction in the number of SNPs
and a 91.6% reduction in the length of
the credible set interval.regulatory annotation also had genome-wide significant
evidence of association in the trans-ethnic analysis
(Figure S4). Then, from overlay of Islet Regulome Browser
data, we found that 8 of 14 substantially narrowed credible
sets for FG and 3 of 9 for FI had either a TFBS or an active
islet-specific enhancer within the narrowed credible regionThe American Journal of H(Figures 2B, 2C, and S4). For example,
the narrowed credible region at the
FOXA2 locus, which also overlaps an
lncRNA as noted above, falls within
an active C3 enhancer cluster and
contains binding sites for both
NKX2-2 and FOXA2, raising the possi-
bility that the causal genetic mecha-
nism at this locus involves regulation
of FOXA2, the lncRNA at the locus,
or both (Figure 2B). The narrowedcredible region at the CRY2 locus also overlaps a C3
enhancer cluster in islets that contains an NKX2-2 TFBS
(Figure 2C). Furthermore, at three FG loci (GCK, ADCY5
[MIM: 600293], and GCKR) and both FI loci (GCKR and
PPP1R3B [MIM: 610541]) whose 99% credible set was nar-
rowed to a single variant, the remaining credible set SNPuman Genetics 99, 56–75, July 7, 2016 63
Table 2. Genomic Annotation Characteristics at 22 EA-Associated Type 2 Diabetes Quantitative Traits Loci with Substantially Reduced
99% Credible Sets Based on Trans-ethnic Fine Mapping
Locusb # SNPsc Syn
dbSNP






FOXA2 2 0 0 1 0 2 2 2 2 2 AT
GCK 1 0 0 0 1 1 0 0 1 1 PT
KL 147 1 0 53 24 122 19 18 94 36 PIACT
ADCY5 1 0 0 1 0 0 0 1 1 1 T
GCKR 1 0 0 1 1 1 1 0 1 0 I
PROX1 5 0 0 0 6 5 1 1 4 1 PAT
DPYSL5 50 1 1 37 23 44 7 9 42 24 PIACT
IGF2BP2 38 0 0 30 32 34 8 8 35 15 PIACT
CDKN2B-ANRIL 5 0 0 0 3 5 0 0 4 2 AT
ADRA2 26 0 0 0 1 22 0 1 12 6 IT
TCF7L2 4 0 0 3 0 2 0 1 3 2 AT
FADS1 16 0 0 12 16 15 7 6 16 10 PAT
DGKB-TMEM195 10 0 0 0 2 8 0 3 10 0 A
CRY2 2 0 0 1 2 2 0 1 2 0 PACT
Fasting Insulin-Associated Loci
ARL15 22 0 0 22 18 18 3 3 17 5 IT
PPP1R3B 1 0 0 1 1 1 0 0 1 0 –
COBLL1-GRB14 3 0 1 0 3 3 1 0 1 0 T
IRS1 13 0 0 0 13 11 1 0 7 2 C
GCKR 1 0 0 1 1 1 1 0 1 0 I
FAM13A 21 0 0 21 18 15 3 8 20 6 PIACT
ANKRD55-MAP3K1 200 0 0 0 63 161 20 17 147 67 IAT
UHRF1BP1 9 0 0 8 9 8 2 0 4 5 PAT
PPARG 11 0 1 10 11 8 2 4 11 5 –
Abbreviations are as follows: Syn, synonymous SNP; non-syn, non-synonymous SNP; eQTL, expression quantitative trait loci; TF motif, transcription factor motif;
TFBS, transcription factor binding site; DHS, DNase l-hypersensitive sites.
aThe information was obtained on December 1, 2014.
bFor ease of comparison to previous studies, the loci (13 fasting glucose, 8 fasting insulin, and 1 more for both) are named based on the historically identified
nearest protein-coding gene or genes to the index SNP in EA.
c#SNPs: the number of SNPs in trans-ethnic analysis-based 99% credible set.
dPIACT: P, I, A, C, and T represent promoter, inactive enhancer, active enhancer, CTCF insulator, and transcription factor binding site (TFBS), respectively.overlapped with regulatory annotation in either ENCODE,
Roadmap, or the Islet Regulome (Table 2). Based on data
derived from the Islet Regulome Browser, all 14 FG and 7
of 9 FI loci had evidence of regulatory function in pancre-
atic islets within the credible set (Table 2). Nearly all loci
with narrowed credible sets contained at least one tran-
scription factor (TF) motif within the 99% credible set
(13/14 FG and 9/9 FI) and had at least one variant associ-
ated with cis-eQTL data (11/14 FG and all 9 FI). In addition,
all 14 FG and 9 FI loci contained some regulatory evidence;
in contrast, only three of the loci (DPYSL5, COBLL1-
GRB14, and PPARG) contained a nonsynonymous variant
in their credible sets (Table 2).64 The American Journal of Human Genetics 99, 56–75, July 7, 2016Relevance of European T2D QT Loci for African
Americans
To evaluate the relevance in AA individuals of genetic de-
terminants of FG and FI identified from EA studies, we
examined SNP and locus association transferability, allele
frequency differences, and patterns of association between
FG/FI SNPs and glycemia-related traits. We tested SNP
transferability (defined as whether the index EA SNP was
associated with the same trait in AA, with the same direc-
tion of effect, and p < 0.05) at 54 EA-associated FG or FI
loci. Of 36 EA FG index SNPs, 11 SNPs reached SNP trans-
ferability criteria (binomial p ¼ 9.87 3 10–8 for observing
11/36 meeting SNP transferability criteria) (Table 3). Of
Figure 2. Trans-ethnic Fine-Mapping of Glycemic Quantitative Trait Loci Highlights Overlap between Trait-Associated SNPs and Pre-
dicted Regulatory Function
(A) Analysis for enrichment of posterior probabilities in SNPs overlapping transcription factor binding sites (TFBSs) and cell-type-specific
enhancer and promoter marks at 22 (13 FG, 8 FI, and 1 both FG and FI) substantially narrowed 99% credible sets. x axis shows fold-
enrichment above null, the y axis shows –log10(P) for enrichment, and FI and FG are indicated by yellow and blue points, respectively.
TFBSs and cell types with enhancer or promoter marks with p value for enrichment below 0.01 are labeled.
(B) Regional association plots for fasting glucose after trans-ethnic analysis demonstrating overlap between regulatory annotation and
narrowed credible regions at the FOXA2 locus.
(C) Regional association plots for fasting glucose after trans-ethnic analysis demonstrating overlap between regulatory annotation and
narrowed credible regions at the CRY2 locus.
(legend continued on next page)
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18 EA index FI SNPs, 2 met SNP transferability criteria
(Table 3). We also found excess concordance in direction
of effect of the SNPs comparing EA with AA samples, irre-
spective of the strength of association: of 36 EA FG index
SNPs, 28 SNPs shared the same direction of effect in the
AA sample (binomial p ¼ 5.97 3 10–4); of 18 EA FI index
SNPs, 14 SNPs shared the same direction of effect in the
AA sample (binomial p¼ 0.015) (Figure S5). For both traits,
SNPs that met transferability criteria tended to have larger
effect sizes than those not meeting the criteria, and the
magnitudes of effect in EAwere similar to those in AA sam-
ples (Figure S5). There was genome-wide excess of direc-
tional concordance of SNP effects comparing EA with AA
(binomial p ¼ 0.021 for FG and binomial p ¼ 0.016 for
FI) when considering SNPs independent of previously re-
ported T2DQTassociations and with p% 0.01 in EA (Table
S8). This evidence supports the hypothesis that trans-
ethnic meta-analysis in large samples could reveal addi-
tional SNPs associated with glycemic traits.
We also evaluated locus transferability (defined as
whether any SNP within 5250 kb of the index EA SNP
was associated with the same trait in AA at a Bonferroni-
corrected p < 0.05) at the 54 EA-associated FG or FI loci.
Loci were transferable from the EA to AA individuals (ad-
justing for the effective number of SNPs tested in each re-
gion) for 15/38 FG loci and for 10/18 FI loci (Table 4,
Figure S2). At six FG loci (GCK, ADCY5, GCKR, CRY2,
PPP1R3B, and MTNR1B [MIM: 600804]) and two FI loci
(PDGFC [MIM: 608452] and GCKR), the index SNPs from
the EA sample and the most significantly associated SNPs
in the AA sample were either in LD (r2 R 0.20) in YRI or
were the same SNP (Table 4). In contrast, for the remaining
loci, the index SNP from the EA sample and the most asso-
ciated SNP in the AA sample were not in LD (r2 < 0.20 in
AA sample). For these loci with low LD between EA index
SNP and the most associated AA SNP, we found a change
in effect size > 10% for the AA SNP after conditioning on
the index SNP in EA at only three FG loci (SLC30A8
[MIM: 611145], PPP1R3B, and GCK) (Table S9). These re-
sults show ancestrally derived allelic heterogeneity giving
more than one variant signal at these FG loci.
Allele Frequency Differences and Selection
FG-raising (38 SNPs) and FI-raising (18 SNPs) allele fre-
quencies for EA index SNPs differed widely comparing
AA with EA populations (absolute allele frequency differ-
ences ranged from 0.007 to 0.825 for FG index SNPs and
0.017 to 0.540 for FI index SNPs) (Table S10, Figure S5).
We estimated Wright’s fixation index (FST)
26 to demon-
strate whether selection pressure has resulted in widely
different allele frequencies at any SNPs in AA versus EA(B and C) The index SNP in European ancestry (MAGIC) is represente
resented by a triangle. SNPs are colored according to the score assign
level of evidence supporting regulatory function; data from the Isl
regional association plots. The interval spanned by the 99% credib
pink regions; interval spanned by the narrowed 99% credible set aft
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to substantial population differentiation for a minority of
FG and FI SNPs: FST > 0.15 at four FG loci (ADRA2A
[MIM: 104210], PCSK1 [MIM: 162150], OR4S1, and
ARAP1 [MIM: 606646]) and at one FI locus (UHRF1BP1)
in the AAGILE and MAGIC data. There was also evidence
of recent positive selection (absolute value of iHS > 2) for
one FG locus (FOXA2) and three FI loci (UHRF1BP1, HIP1
[MIM: 601767], and MAP3K19) in the EA, yet no evidence
of recent selection in AA (Table S10).
Associations between FG/FI SNPs and Insulin
Resistance-Related Metabolic Traits
Many FG/FI-associated loci identified in EA samples were
also associated with T2D and other insulin resistance-
related traits.8,9 We investigated these associations in AA
individuals at 25 SNPs, including 24 AA SNPs (14 FG, 9
FI, and 1 associated with both FG and FI) at loci that
showed transferability, plus the previously undescribed FI
SNP (rs6450057) described in the next section. A second
FI SNP (also described in the next section), rs213676, was
not interrogated for association with metabolic traits due
to scant chromosome X data. Table S11 summarizes the
association results of these 25 FG/FI SNPs with T2D,
body mass index (BMI), BMI-adjusted waist-to-hip ratio
(WHR), blood pressure, hypertension (HTN), and lipid
levels in AA from several consortia.32–36,42 14 of 25 (56%)
FG/FI SNPs were associated with T2D or an insulin resis-
tance-related trait (p < 0.05 with an effect in the expected
direction [e.g., FG-raising SNP associated with increased
risk of T2D]). Six SNPs (24%; 4 [ADCY5, RREB1 (MIM:
602209), MTNR1B (MIM: 600804), and FOXA2] of 15 FG
SNPs and 2 [COBLL1-GRB14 and ARL15] of 11 FI SNPs)
were associated with higher odds of T2D in AA samples
(n up to 23,818).31 40% (6/15) of the FG-raising alleles
and 45% (5/11) of the FI-raising alleles were associated
with insulin resistance-related traits in AA samples. The
FI SNP rs6717858 (COBLL1-GRB14) was associated with
three traits (T2D, BMI-adjusted WHR, and HDL-C).
rs17811863 (PDGFC), also an FI SNP, was associated with
both systolic and diastolic blood pressure.
Previously Undescribed Glycemic Quantitative
Trait Loci
The strategy we used for glycemic loci discovery in AAGILE
is shown in Figure S1. Results of the discovery analysis are
shown in Figure S6. AAGILE GWAS results were combined
with MAGIC EA GWAS results10 in a two-stage meta-anal-
ysis approach. In the discovery stage, results from 16
studies (n ¼ 20,209) in the AAGILE AA GWAS fixed effects
meta-analysis were combined with results from 29 studiesd by a diamond; the best SNP in African ancestry (AAGILE) is rep-
ed in RegulomeDB11 with lower score corresponding to stronger
et Regulome Browser13 for the genomic interval is shown below
le set using EA data only is represented by combining blue and
er trans-ethnic analysis is shown in pink.
Table 3. SNP Transferability in AA Individuals at 13 EA-Associated Type 2 Diabetes Quantitative Trait SNPs
Locusb Index SNPc Chr Allelesd
EA Associationa AA Associationa
EAFe Effectf SE EAFe Effectf SE p
Fasting Glucose-Associated Loci
MTNR1B rs10830963 11 G/C 0.30 0.067 0.003 0.08 0.089 0.012 9.29 3 10–15
G6PC2 rs560887 2 C/T 0.70 0.075 0.003 0.93 0.059 0.013 2.67 3 10–06
ADCY5 rs11708067 3 A/G 0.78 0.027 0.003 0.85 0.036 0.008 6.27 3 10–06
GCKR rs780094 2 C/T 0.62 0.029 0.003 0.82 0.032 0.008 2.03 3 10–05
GCK rs4607517 7 A/G 0.16 0.062 0.004 0.11 0.041 0.010 6.84 3 10–05
GLIS3 rs7034200 9 A/C 0.49 0.018 0.003 0.63 0.019 0.006 1.82 3 10–03
KL rs576674 13 G/A 0.15 0.017 0.003 0.60 0.018 0.006 2.06 3 10–03
SLC30A8 rs13266634 8 C/T 0.68 0.027 0.004 0.90 0.024 0.010 1.82 3 10–02
MADD rs7944584 11 A/T 0.75 0.021 0.003 0.95 0.029 0.014 3.37 3 10–02
DGKB-TMEM195 rs2191349 7 T/G 0.52 0.030 0.003 0.60 0.013 0.006 3.70 3 10–02
GRB10 rs6943153 7 T/C 0.34 0.015 0.002 0.68 0.012 0.006 4.81 3 10–02
Fasting Insulin-Associated Locig
COBLL1-GRB14 rs7607980 2 T/C 0.87 0.027 0.004 0.84 0.042 0.008 2.85 3 10–07
GCKR rs780094 2 C/T 0.62 0.032 0.004 0.82 0.025 0.008 1.92 3 10–03
SNP transferability is defined as the association p< 0.05 in AA and sharing the same trait-raising allele between EA and AA. 13 EA-identified T2DQT SNPs in 12 loci,
including 10 fasting glucose loci, 1 fasting insulin locus, and 1 locus associated with both.
aEA Association results refer to the association results using samples of European ancestry in previous publications;8–10 AA Association results refer to the association
results using AAGILE samples of African ancestry assembled in this study.
bFor ease of comparison to previous studies, the loci are named based on the historically identified nearest protein-coding gene or genes to the index SNP in Eu-
ropean ancestry.
cIndex SNPs are the most significant SNPs previously reported in MAGIC publications. All of these SNPs reach genome-wide significant level (p < 53 10–8) in the
original study.
dEA trait-raising allele/other allele.
eFrequency of EA trait-raising allele.
fEffect of EA trait-raising allele ([mmol/L] for fasting glucose and [pmol/L] for fasting insulin per trait-raising allele).
gThe association with BMI-adjusted fasting insulin.(n ¼ 57,292) from the MAGIC EA GWAS10 for trans-ethnic
meta-analysis using MANTRA. A total of 62 SNPs met pre-
specified multi-tiered criteria for stage 2 follow-up, with 12
SNPs in tier 1, 10 in tier 2, and 40 in tier 3 (Figure S1 and
Table S12). Follow-up in the second stage, with up to
10,096 additional AA samples from 14 studies (Table S1),
yielded two previously undescribed SNPs in loci associated
with FI that exceeded GWAS significance thresholds (Table
5). We found no previously unknown FG loci.
In the fixed effects meta-analysis of AA samples, we iden-
tified a previously undescribed SNP (rs213676) on chromo-
some X near FAM133A associated with FI (p ¼ 2.4 3 10–8)
(Figure 3A). This FI SNP was not included in the trans-
ethnic meta-analysis because MAGIC10 did not report
chromosome X results. Although rs213676 is in a region
without known genes, this region might be of regulatory
significance because it is known to harbor a TFBS in
pancreatic islets11,13 (Figure 3A).
The other previously undescribed FI SNP, rs6450057 on
chromosome 5 (Figure 3B), resides near four putative
lncRNA genes and the PELO (MIM: 605757) (or ITGA1
[MIM: 192968]) gene. In trans-ethnic analyses, this locus
achieved genome-wide significance (log(BF) ¼ 7.1) andThtrans-ethnic fine-mapping reduced the credible set at this
locus from 229 SNPs to just 3 SNPs. Interestingly, the
rs6450057 T allele is associated with higher FI (p ¼ 3.1 3
10–6) in AA samples but with lower FI (p ¼ 9.2 3 10–5) in
EA samples in ancestry-specific fixed-effect meta-analyses
(Table 5). The discordant direction of effect at this locus
was observed across nearly all SNPs at the locus, regardless
of LD with rs6450057 (Figure 3C). However, the direction
of effects did not show a clear pattern in the association
analysis after conditioning on rs6450057, implying that
the signal at this locus was driven by rs6450057
(Figure S7). As withmany of the glycemic QT loci described
above, the 99% credible set at this locus did not include
coding variants but did overlap an active C3 enhancer in
pancreatic islets11,13 (Figure 3D).Discussion
We assembled a large sample of AA individuals, combined
resulting data with published data from EA individuals,
and used trans-ethnic finemapping to narrow the genomic
interval containing putative causal SNPs for 22 of 54e American Journal of Human Genetics 99, 56–75, July 7, 2016 67
previously identified FI and FG loci. We demonstrated that
many of the genetic variants associated with FG and FI are
predicted to have regulatory function, with few having
predicted protein-coding function. The results show that
although a substantial portion of the genetic architecture
underlying these T2D-associated traits is shared across EA
and AA populations, allelic heterogeneity suggests that
there are also genetic variants unique to AA populations.
Finally, we identified two previously undescribed FI loci,
bringing to 56 the number of FG- and FI-associated loci
in humans.
Fine mapping combined with regulatory annotation
provides a plausible functional explanation for the many
T2D-associated GWAS loci that reside in non-protein-cod-
ing regions of the genome.43–45 Previous GWAS findings
from MAGIC show complete overlap of loci associated
with HOMA-B (a measure of beta cell function46) and
FG,9 so it would be expected that fine-mapping of FG
loci might identify regulatory function in islets. On the
other hand, FI is typically considered a marker of insulin
resistance.47 However, insulin resistance does not account
for all of the variability in FI,48,49 and fasting hyperinsuli-
nemia itself, due to hypersecretion of insulin by beta cells,
might be causal in the pathogenesis of T2D.50–52 Our
finding that some FI loci had predicted regulatory function
in islets is supportive of this evidence. At many loci, for
instance at FOXA2 and PPP1R3B, the narrowed credible
sets from trans-ethnic analysis coupled with genomic
annotation focused attention on lncRNA transcripts rather
than the nearest protein-coding gene, by convention
generally assumed to be the putative causal transcript. At
the FOXA2 locus, the trans-ethnic credible set combined
with genomic annotation highlights regulatory function-
ality in glycemia-related tissues—enhancer marks and
TFBS in pancreas and liver—as well as an lncRNA that
might affect FOXA2 expression, raising two possible causal
regulatory mechanisms for altered FG.12,13,41 Awareness of
the regulatory nature of some genetic determinants of FG
and FI provides insight into novel approaches for the regu-
lation of glucose homeostasis. In particular, regulatory tar-
gets might be amenable to post-genomic manipulation
(e.g., by genome editing, use of antisense oligonucleotides,
or enzyme hijacking) as suggested in other areas.53,54 For
instance, by knowing that polymorphisms in aldehyde de-
hydrogenase 2 (ALDH2) enzyme are associated with poor
alcohol metabolism in some Asian populations, the
enzyme hijacking technique has been used to upregulate
a related, but naturally unimportant, enzyme (ALDH3A1),
thereby improving alcohol metabolism and reducing can-
cer risk in mice.53 Such techniques could in the future be
extended to T2D prevention and control if accessible regu-
latory pathways are elucidated.
At the GCKR locus, trans-ethnic fine mapping provided
added information to the prior knowledge of this locus
identified from studies in EA populations. The 99% cred-
ible set constructed using trans-ethnic analysis results at
GCKR contained only one non-coding SNP, rs78009468 The American Journal of Human Genetics 99, 56–75, July 7, 2016(GenBank: NC_000002.12; g.27518370T>C), the most
strongly FG-associated SNP in both EA and AA. However,
prior fine-mapping39 in EA and functional studies40 have
implicated rs1260326, a nonsynonymous variant (Gen-
Bank: NC_000002.12; g.27508073T>C [p.Leu446Pro]), as
a likely causal SNP at this locus. This missense variant
was excluded from the narrowed credible set. This could
imply that the lead non-coding SNP rs780094, which has
strong evidence as residing in a TFBS, is also a causal
variant at the locus (Table S5). On the basis of statistical ev-
idence, we were unable to distinguish the association of
these two SNPs in EA samples due to high LD (r2 ¼ 0.93).
However, in AA the evidence of association with FG was
several orders of magnitude stronger for the non-coding
SNP, rs780094 (p ¼ 2.2 3 10–5), than the coding SNP,
rs1260326 (p ¼ 0.03) and their LD is weaker (r2 ¼ 0.47).
Both SNPs may play a role at the GCKR locus; a causal
variant tagged by rs780094 might be common to both
ancestries, resulting in the narrowed trans-ethnic credible
set observed here, while the nonsynonymous variant
rs1260326 might have greater functional impact in EA
than in AA individuals. Alternatively, the actual causal
SNP could be in LD with both of these SNPs, and more
dense imputation or deep sequencing might reveal addi-
tional SNPs carried on haplotypes with these SNPs. Since
crystal structural analysis of the GCKR protein has not
identified the 446 residue as critical for binding of
regulating molecules (fructose 1-phosphate and fructose
6-phosphate), genetic heterogeneity involving both cod-
ing and regulatory functional variation at the locus re-
mains a plausible hypothesis.55
Analyses of the relevance of glycemic QT loci in AA
suggest that genetic determinants of human glucose regu-
lation are more similar than different across human popu-
lations. We observed an excess of consistency in direction
of effect of FG and FI SNPs comparing AA with EA, regard-
less of statistical significance of SNPs in AA, and a substan-
tial portion (50% for FG and 56% for FI) of EA index SNP or
loci were transferable to AA individuals. As in previous
studies in EA individuals,8,9 most of the transferable T2D
EA loci were also associated with T2D or insulin resis-
tance-related traits in AA individuals, demonstrating com-
mon genetic pathways underlying glycemic QTs and other
metabolic traits. We also found that several FG-raising and
FI-raising alleles were at least nominally associated with
lower odds of T2D or ‘‘better’’ metabolic trait profiles in
the AA samples. Many of the loci previously observed
to have this discordant pattern of associations across traits
in EA, including GCKR,9,39,40,56,57 MADD (MIM: 603584),9
PDGFC,10 and FOXA2,10 had a similar pattern in our
AA sample, demonstrating that the complexity of the ge-
netic architecture of these traits is shared across
populations.
By combining AA with EA information, including chro-
mosome X variants in AA, we identified two previously un-
described FI SNPs near FAM133A and PELO, increasing the
total number of human FG/FI-associated loci from 54 to
Table 4. Locus Transferability in African Individuals for 24 EA-Identified Type 2 Diabetes Quantitative Traits Associations
Locusb
SNP Information Best SNP Association
adj-ph Effectc
i % Change in Effectj
LDa in YRI and CEU
Index SNP in EAc Best SNP in AAd Best SNP Allelese EAFf Effectuc




MTNR1B rs10830963 rs10830963 G/C 0.079 0.089 0.012 9.3 3 10–15 3.5 3 10–3 NA NA 1.00 1.00 1.00 1.00
GCK rs4607517 rs1799884 T/C 0.174 0.047 0.007 2.0 3 10–10 8.6 3 10–3 0.038 19.3 0.47 1.00 1.00 1.00
G6PC2 rs560887 rs830193 C/T 0.816 0.037 0.008 1.2 3 10–6 2.9 3 10–3 0.035 5.2 0.00 0.08 0.07 0.58
FOXA2 rs6048205 rs1203907 T/C 0.505 0.027 0.006 3.7 3 10–6 3.3 3 10–3 0.025 7.7 0.18 0.92 0.66 1.00
RREB1 rs17762454 rs557074 G/T 0.455 0.027 0.006 4.2 3 10–6 4.1 3 10–3 0.025 4.4 0.01 0.48 0.02 0.51
SLC30A8 rs13266634 rs10505311 G/T 0.837 0.036 0.008 5.6 3 10–6 3.7 3 10–3 0.025 30.8 0.19 1.00 NA NA
ADCY5 rs11708067 rs11708067 A/G 0.846 0.036 0.008 6.3 3 10–6 4.5 3 10–3 NA NA 1.00 1.00 1.00 1.00
GCKR rs780094 rs780094 C/T 0.819 0.032 0.008 2.0 3 10–5 1.4 3 10–2 NA NA 1.00 1.00 1.00 1.00
CRY2 rs11605924 rs11038651 T/C 0.828 0.033 0.008 3.8 3 10–5 5.3 3 10–3 0.030 9.4 0.55 0.85 0.12 0.44
MADD rs7944584 rs1052373 T/C 0.481 0.022 0.006 1.4 3 10–4 1.1 3 10–2 0.022 0.0 NA NA 0.15 1.00
PPP1R3B rs4841132 rs7004769 A/G 0.228 0.024 0.007 2.7 3 10–4 2.2 3 10–3 0.018 26.1 0.44 1.00 0.38 1.00
PROX1 rs340874 rs2282387 C/G 0.519 0.021 0.006 4.6 3 10–4 3.4 3 10–3 0.021 –1.2 0.01 0.27 0.00 0.09
IKBKAP rs16913693 rs7038936 C/T 0.669 0.021 0.006 5.3 3 10–4 3.9 3 10–3 NAk NA 0.04 0.29 0.01 0.39
ADRA2A rs10885122 rs12569523 A/T 0.368 0.021 0.006 5.4 3 10–4 3.6 3 10–3 0.020 1.9 0.01 0.11 0.00 0.25
PCSK1 rs13179048 rs7722200 T/C 0.773 0.023 0.007 8.2 3 10–4 7.0 3 10–3 0.023 –0.9 0.04 1.00 0.66 0.83
Fasting Insulin-Associated Loci
COBLL1-GRB14 rs7607980 rs6717858 T/C 0.281 0.036 0.007 8.6 3 10–8 5.3 3 10–3 0.034 6.4 0.06 1.00 0.22 1.00
ARL15 rs4865796 rs6876198 C/T 0.295 0.031 0.007 2.0 3 10–6 3.8 3 10–3 0.030 4.0 0.11 0.89 0.09 0.87
PPP1R3B rs4841132 rs9949 G/A 0.231 0.029 0.007 6.9 3 10–5 2.2 3 10–3 0.027 6.7 0.11 0.51 0.01 0.23
IRS1 rs2943634 rs4413154 G/A 0.041 0.062 0.016 1.2 3 10–4 4.9 3 10–3 0.062 1.3 0.01 1.00 0.08 1.00
ANKRD55-MAP3K1 rs459193 rs7700714 A/G 0.436 0.023 0.006 1.8 3 10–4 2.3 3 10–3 0.024 –3.6 0.00 0.03 0.04 0.29
FAM13A rs3822072 rs17799176 C/G 0.934 0.043 0.012 4.3 3 10–4 5.8 3 10–3 0.043 0.2 0.00 0.22 0.02 0.43
HIP1 rs1167800 rs11465341 C/T 0.035 0.060 0.017 4.5 3 10–4 8.1 3 10–3 0.060 0.0 0.00 1.00 NA NA
MAP3K19 rs1530559 rs13405563 T/C 0.924 0.043 0.013 5.5 3 10–4 8.8 3 10–3 0.045 –3.6 0.00 0.79 0.04 1.00
PDGFC rs4691380 rs17811863 G/A 0.333 0.022 0.006 6.2 3 10–4 4.7 3 10–3 0.020 8.9 0.21 0.49 0.77 0.93
GCKR rs780094 rs780094 C/T 0.817 0.025 0.008 1.9 3 10–3 1.4 3 10–2 NA NA 1.00 1.00 1.00 1.00
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































70 The American Journal of Human Genetics 99, 56–75, July 7, 201656. The lead SNP at the PELO locus, rs6450057, had discor-
dant effects in the AA and EA samples: the FI-raising allele
in AA lowered FI in EA. Discordant effects of common var-
iants on complex human traits have been observed in
other traits such as breast cancer58 and serum protein
levels59 but not in T2D QT. This may be due to the lack
of trans-ethnic study of T2D QT, the use of fixed-effects ap-
proaches that do not adequately account for heterogeneity
in LD or allelic frequencies across populations, gene-envi-
ronment interactions with differential exposures across
ancestral populations, or gene-gene interactions with sub-
stantially different allele frequencies for the interacting
variants across ancestries. Alternatively, EA and AA groups
may have different causal variants that are in moderate LD
with the lead SNP, thus boosting the association signal in
trans-ethnic meta-analyses that take account of the hetero-
geneity in allelic effects between ancestry groups. Haplo-
type analysis in both EA and AA samples did not clearly
elucidate differential SNP contributions to FI levels at the
PELO locus. Although our analyses are unable to distin-
guish between possible mechanisms driving the discor-
dant effects of rs6450057 in EA and AA populations, eval-
uation of the locus, with high-density imputation and/or
whole-genome sequencing data from individuals of EA
and AA as well as laboratory-based examination of the clus-
tered enhancer in pancreatic islets at this locus, could help
explain the observed divergent associations.
A major strength of this investigation was the large sam-
ple size of AA, a hitherto under-studied ancestral group
with a heavy burden of hyperglycemia, insulin resistance,
and T2D. The large sample of AA individuals allowed
genome-wide trans-ethnic discovery, fine-mapping, and
(combined with new annotation resources) detailed pre-
diction of regulatory function. Yet, despite the large sample
size, our study still had modest power to detect loci with
small effects. With sample size of 30,305 (discovery þ
follow up) in AA, we had only 15% power to detect an
EA-identified median FG effect size of 0.0196 mmol/L
with SD of 0.5 mmol/L, for variants with MAF of 0.3. In
addition, the reduced size of LD blocks in AA populations
decreased the probability that a tagging SNP resided on the
same haplotype as a causal variant, further limiting power
for discovery. Also, reduced LD haplotype and correspond-
ing greater genetic diversity made imputation for AA sam-
ples more challenging. The HapMap2 panel, used as the
imputation panel for majority of contributing studies in
this analysis, did not provide complete coverage of com-
mon and low-frequency genetic variation in AA samples;
the latest reference panels from 1000 Genomes Phase 3
should provide better coverage although whole-genome
sequencing and laboratory analysis of genetic function
are going to be necessary to unequivocally determine
causal variants that may have similar or different effects
across ancestral groups. As for other trans-ethnic ef-
forts,16,60 we have reported the improvement in fine-map-
ping resolution in terms of the reduction in the number of






















































































































































































































































































































































































































































































































































































































































































































































































































Thmap. The improvement from trans-ethnic analysis varied
from one locus to another as shown in Table S2. We used
20% reduction in credible set size to provide an overall
assessment of fine-mapping resolution (albeit crude). How-
ever, fine-mapping resolutions depends on many factors,
such as the size of LD blocks and the availability of high-
quality read-depth for the reference datasets used in the
imputation, and will therefore vary from one locus to
another. Furthermore, the improvement in resolution
offered by trans-ethnic meta-analysis relies on the extent
of LD differences with the causal variant between ancestry
groups and the increase in sample size. However, impor-
tantly, credible set sizes can increase after trans-ethnic
meta-analysis, which most often occurs due to different
underlying causal variants across ancestry groups. In this
scenario, the credible set captures multiple association sig-
nals driven by each causal variant, which will therefore be
larger than that observed for ethnic-specific analyses.
In conclusion, by using AA and EA trans-ethnic analysis,
we narrowed the genomic interval containing likely causal
variants for a large number of biologically plausible FG and
FI loci and demonstrated that many FG and FI loci prob-
ably have regulatory, rather than protein-coding, function.
The observed effects of genetic variants on glycemic traits
might result from multiple regulatory functions residing
in the same genomic region; for example, concurrent pres-
ence of an enhancer and lncRNA at the FOXA2 locus, an
attribute that could lead to synergy in function. We also
showed that there are probably both shared and unique ge-
netic determinants of T2D QTs across European and Afri-
can ancestral populations. We identified two previously
undescribed FI loci, bringing the total number of identified
FG and FI loci in humans to 56. Our finding of the pre-
dicted regulatory significance of many FG and FI loci is
particularly noteworthy, given the prior uncertainty about
the functional relevance of most GWAS findings for T2D
and related QTs. Our study provides a framework for
further follow-up of GWAS signals seen in EA and other
ancestral populations. This approach using trans-ethnic
meta-analysis for discovery and transferability combined
with trans-ethnic fine-mapping and state-of-the-art anno-
tation will lead the way to an understanding of the func-
tional, and ultimately therapeutic, implications of genetic
variation underlying glucose homeostasis, T2D risk, and
other complex disorders.Supplemental Data
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Figure 3. Regional Association Plots and Functional Annotation for Two Previously Undescribed Loci
(A) Regional association plot of a previously undescribed chromosome X locus associated with fasting insulin in AA individuals. The
nearest gene is FAM133A. Top panel shows association signal on the y axis (log(P)) and genomic position on chromosome X on the
x axis. The red diamond data point represents the lead SNP (rs213676) within the region. The blue line represents the recombination
(legend continued on next page)
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